Aptevo Therapeutics (NASDAQ:APVO) Trading Up 3% – Should You Buy?

Aptevo Therapeutics Inc. (NASDAQ:APVO)’s stock price was up 3% during mid-day trading on Thursday . The company traded as high as $4.86 and last traded at $4.86. Approximately 15,800 shares traded hands during trading, a decline of 54% from the average daily volume of 34,356 shares. The stock had previously closed at $4.72.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on APVO shares. Wall Street Zen upgraded Aptevo Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, March 29th. Weiss Ratings cut Aptevo Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a report on Tuesday, May 26th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold”.

Aptevo Therapeutics Stock Performance

The stock has a market cap of $6.08 million, a PE ratio of -0.02 and a beta of 1.68. The stock has a fifty day simple moving average of $4.83 and a two-hundred day simple moving average of $8.69.

Aptevo Therapeutics (NASDAQ:APVO) last released its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($6.41) earnings per share for the quarter, hitting analysts’ consensus estimates of ($6.41). On average, equities analysts predict that Aptevo Therapeutics Inc. will post -24.13 EPS for the current fiscal year.

Hedge Funds Weigh In On Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Virtu Financial LLC bought a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned about 1.16% of Aptevo Therapeutics at the end of the most recent quarter. Institutional investors own 8.06% of the company’s stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.